Trastuzumab is recommended for HER2-overexpressing EAC, while ICIs show efficacy in HER2-negative adenocarcinomas with high or intermediate PD-L1 expression or deficient mismatch repair [98]. This evidence concerns the gene ERBB2 and adenocarcinoma.